Polypid Ltd (PYPD)

$4.16 -0.21 (-4.81%)
Market Cap 79.39M
Revenue (ttm) 0.00
Net Income (ttm) -34.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 44,300
Avg Vol 59,516
Day's Range N/A - N/A
Shares Out 19.08M
Stochastic %K 13%
Beta 1.49
Analysts Strong Sell
Price Target $12.25

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in precl...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 4719 5700
Address:
18 Hasivim Street, Petah Tikva, Israel
Finnish_boy
Finnish_boy Mar. 21 at 8:35 AM
$PYPD March 17, 2026: "We are pleased to receive this PDUFA fee waiver days before our planned NDA submission" March 23, 2026, at 12:30 PM PT: "38th Annual ROTH Conference" NDA submission Monday morning? Or Tuesday. Would be logical to press release around conference to get more attention. But yes, at the latest 31th Tuesday. Doesnt matter when. But if goal was by the end of March, NDA submission likely earlier than final day.
0 · Reply
Finnish_boy
Finnish_boy Mar. 21 at 6:57 AM
$PYPD But NDA submission in March and US partner in April. And Polypid gets attention when these news are out and buyers find this. Under radar status is gone and stock doubles. Stock can double in a month already. Attention is big deal when stock is crazy undervalued and tiny market cap and volume.
0 · Reply
Finnish_boy
Finnish_boy Mar. 20 at 7:59 PM
$PYPD I dont expect crazy returns in weeks. My PT $10 by Q2. 100% gains in 3 months are enough? Yes.
0 · Reply
Finnish_boy
Finnish_boy Mar. 20 at 7:56 PM
$PYPD Party starts next week or week after. Patience. I bought more today. US partner in weeks. Patience. Lock in. Wait. Get rich.
0 · Reply
PaulWalter
PaulWalter Mar. 20 at 1:49 PM
$PYPD man this is dead. Very disappointing.
3 · Reply
PaulNipkow
PaulNipkow Mar. 20 at 8:01 AM
$PYPD Took a starter after first DD- like the product
0 · Reply
Alberthansson02
Alberthansson02 Mar. 19 at 11:51 AM
$PYPD added some more yesterday after doing some more research!
0 · Reply
pandodark
pandodark Mar. 18 at 1:48 PM
$PYPD Massive upside potential. FDA wouldn’t waive fees if there was any doubt of approval. Low market cap at the moment. Not for long…
1 · Reply
WallStWireAds
WallStWireAds Mar. 18 at 1:10 PM
$PYPD PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention >> https://www.benzinga.com/content/51322617/polypid-approaches-nda-submission-as-new-medicare-model-creates-strong-incentives-for-ssi-prevention
1 · Reply
lelXYpics
lelXYpics Mar. 17 at 5:37 PM
$PYPD yet another important indication and vote of confidence; Polypid is much needed in the market; coming soon. https://investors.polypid.com/news-releases/news-release-details/polypid-receives-pdufa-fee-waiver-fda-d-plex100s-new-drug
0 · Reply
Latest News on PYPD
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Mar 17, 2026, 8:30 AM EDT - 4 days ago

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 25, 2026, 8:35 AM EST - 24 days ago

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 3:24 PM EST - 5 weeks ago

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 7:30 AM EST - 5 weeks ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Jan 28, 2026, 8:00 AM EST - 7 weeks ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 16, 2025, 8:30 AM EST - 3 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

Dec 10, 2025, 4:42 PM EST - 3 months ago

PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Dec 3, 2025, 8:30 AM EST - 3 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 25, 2025, 8:30 AM EST - 4 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:51 PM EST - 4 months ago

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:30 AM EST - 4 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Nov 6, 2025, 8:30 AM EST - 4 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Oct 29, 2025, 8:30 AM EDT - 5 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 30, 2025, 8:45 AM EDT - 6 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 8:44 AM EDT - 6 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 16, 2025, 8:30 AM EDT - 6 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 7 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Sep 2, 2025, 8:30 AM EDT - 7 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:52 PM EDT - 7 months ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:30 AM EDT - 7 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 7 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 30, 2025, 8:00 AM EDT - 8 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jul 15, 2025, 8:00 AM EDT - 8 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 16, 2025, 7:20 PM EDT - 9 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:42 AM EDT - 10 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 10 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:54 AM EDT - 10 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 9, 2025, 7:30 AM EDT - 10 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Jun 6, 2025, 4:05 PM EDT - 10 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 30, 2025, 10:12 AM EDT - 10 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 20, 2025, 7:00 AM EDT - 10 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:24 PM EDT - 11 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 7:00 AM EDT - 11 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 29, 2025, 7:00 AM EDT - 11 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Participate in The Citizens Life Sciences Conference

Apr 22, 2025, 7:00 AM EDT - 11 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 10:44 AM EST - 1 year ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 2:06 PM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Finnish_boy
Finnish_boy Mar. 21 at 8:35 AM
$PYPD March 17, 2026: "We are pleased to receive this PDUFA fee waiver days before our planned NDA submission" March 23, 2026, at 12:30 PM PT: "38th Annual ROTH Conference" NDA submission Monday morning? Or Tuesday. Would be logical to press release around conference to get more attention. But yes, at the latest 31th Tuesday. Doesnt matter when. But if goal was by the end of March, NDA submission likely earlier than final day.
0 · Reply
Finnish_boy
Finnish_boy Mar. 21 at 6:57 AM
$PYPD But NDA submission in March and US partner in April. And Polypid gets attention when these news are out and buyers find this. Under radar status is gone and stock doubles. Stock can double in a month already. Attention is big deal when stock is crazy undervalued and tiny market cap and volume.
0 · Reply
Finnish_boy
Finnish_boy Mar. 20 at 7:59 PM
$PYPD I dont expect crazy returns in weeks. My PT $10 by Q2. 100% gains in 3 months are enough? Yes.
0 · Reply
Finnish_boy
Finnish_boy Mar. 20 at 7:56 PM
$PYPD Party starts next week or week after. Patience. I bought more today. US partner in weeks. Patience. Lock in. Wait. Get rich.
0 · Reply
PaulWalter
PaulWalter Mar. 20 at 1:49 PM
$PYPD man this is dead. Very disappointing.
3 · Reply
PaulNipkow
PaulNipkow Mar. 20 at 8:01 AM
$PYPD Took a starter after first DD- like the product
0 · Reply
Alberthansson02
Alberthansson02 Mar. 19 at 11:51 AM
$PYPD added some more yesterday after doing some more research!
0 · Reply
pandodark
pandodark Mar. 18 at 1:48 PM
$PYPD Massive upside potential. FDA wouldn’t waive fees if there was any doubt of approval. Low market cap at the moment. Not for long…
1 · Reply
WallStWireAds
WallStWireAds Mar. 18 at 1:10 PM
$PYPD PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention >> https://www.benzinga.com/content/51322617/polypid-approaches-nda-submission-as-new-medicare-model-creates-strong-incentives-for-ssi-prevention
1 · Reply
lelXYpics
lelXYpics Mar. 17 at 5:37 PM
$PYPD yet another important indication and vote of confidence; Polypid is much needed in the market; coming soon. https://investors.polypid.com/news-releases/news-release-details/polypid-receives-pdufa-fee-waiver-fda-d-plex100s-new-drug
0 · Reply
PokerMunkee
PokerMunkee Mar. 17 at 4:27 PM
$PYPD Loading. Will sell half at $10 and let rest ride.
0 · Reply
trademama87
trademama87 Mar. 17 at 3:35 PM
$PYPD Great PR. We are on 👏🏻 track 👏🏻. Looking forward to the US Partnership announcement in the next month or so. Great opportunity here. I was already loaded up but added even more this morning. 🔥
1 · Reply
TomiGurArie
TomiGurArie Mar. 17 at 2:22 PM
$PYPD this could go way over 20 usd
0 · Reply
Alberthansson02
Alberthansson02 Mar. 17 at 1:54 PM
$PYPD Added a big chunk!!
0 · Reply
DASmyth
DASmyth Mar. 17 at 1:50 PM
$PYPD We just saved $4.3 million dollars—I’d say that’s a good day. Very very
0 · Reply
tkcomputer
tkcomputer Mar. 17 at 1:21 PM
$PYPD This thing is about to take off. The more research I do the more impressive this looks!!
0 · Reply
Finnish_boy
Finnish_boy Mar. 17 at 12:45 PM
$PYPD My final warning. LOAD UP THE TRUCK UNDER $5 !!
0 · Reply
Finnish_boy
Finnish_boy Mar. 17 at 12:42 PM
$PYPD YES, US PARTNER IN WEEKS !! "we are in advanced stages of commercial partnership discussions for the U.S. market while preparing for what we expect to be a transformative year for PolyPid."
0 · Reply
Finnish_boy
Finnish_boy Mar. 17 at 12:41 PM
$PYPD "Company On Track to Initiate NDA Submission by the End of this Month"🚨
0 · Reply
Finnish_boy
Finnish_boy Mar. 17 at 12:39 PM
$PYPD "We are pleased to receive this PDUFA fee waiver days before our planned NDA submission" Good luck guys! See you at $10. NDA submission next Monday my best guess. But in 2 weeks 100% sure!! US partnership can be massive also!!
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 17 at 12:32 PM
$PYPD - PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
0 · Reply
WallStWireAds
WallStWireAds Mar. 17 at 12:32 PM
$PYPD https://www.globenewswire.com/news-release/2026/03/17/3257177/0/en/PolyPid-Receives-PDUFA-Fee-Waiver-from-FDA-for-D-PLEX-s-New-Drug-A
0 · Reply